This is a very broad question intended to initiate an exchange of ideas or current best practices from which we can all benefit and promote the the practice of continuous manufacturing: In transitioning from discrete batch manufacturing - be it API or pharmaceutical processing - how have you or how would you modify your current quality control methodologies to ensure product quality while simultaneously mitigating financial risks? Please share your experiences, your successes and challenges.